Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 5:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 5,161 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cervical Clear all
Recruiting Phase 1 Interventional

Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients

NCT04038619
View directory record Official record
Conditions
Colitis, Diarrhea, Malignant Genitourinary System Neoplasm, Melanoma, Lung Cancer, Ovarian Cancer, Uterine Cancer, Breast Cancer, Cervical Cancer
Interventions
Fecal Microbiota Transplantation, Loperamide
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 29, 2026, 5:43 PM EDT
Terminated Phase 1 Interventional

Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors

NCT04190628
View directory record Official record
Conditions
Advanced Solid Tumor, BRAF V600 Mutation
Interventions
ABM-1310, Cobimetinib
Drug
Lead sponsor
ABM Therapeutics Corporation
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
8
States / cities
San Francisco, California • Stanford, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Oct 29, 2026, 5:43 PM EDT
Completed Phase 4 Interventional Results available

Addition of Buprenorphine to Paracervical Block for Pain Control During Osmotic Dilator Insertion

NCT04254081
View directory record Official record
Conditions
Procedural Pain, Buprenorphine, Adjuvants, Anesthesia, Dilation and Evacuation, Analgesics
Interventions
Buprenorphine 0.15 MG, Lidocaine 1% Injectable Solution
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 29, 2026, 5:43 PM EDT
Terminated Phase 1 Interventional

Phase I Dose Escalation of Stereotactic Radiosurgical Boost for Locally Advanced Esophageal Cancer

NCT00368329
View directory record Official record
Conditions
Esophageal Neoplasms, Carcinoma, Squamous Cell, Adenocarcinoma, Esophageal Cancer
Interventions
Capecitabine (Xeloda), [18-F] Fluorodeoxyglucose (FDG), 5-Fluorouracil (5-FU), Carboplatin
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2012 · Synced Oct 29, 2026, 5:43 PM EDT
Recruiting Phase 2 Interventional

sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)

NCT05332002
View directory record Official record
Conditions
Gastro-Intestinal Cancer
Interventions
Four week alternating FOLFOX and FOLFIRI (sFOLFOXIRI)
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
6
States / cities
Hamilton, New Jersey • Lakewood, New Jersey • Long Branch, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 29, 2026, 5:43 PM EDT
Recruiting No phase listed Observational

New MRI Biomarkers in Head and Neck Cancers

NCT03483337
View directory record Official record
Conditions
Head and Neck Cancer, Thyroid Cancer
Interventions
MRI examinations
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 29, 2026, 5:43 PM EDT
Active, not recruiting Phase 2 Interventional

Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers

NCT03403465
View directory record Official record
Conditions
Cancer of the Cervix, Vulvar Cancer, Esophageal Cancer, Anal Canal Cancer
Interventions
FDG PET scan
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 29, 2026, 5:43 PM EDT
Completed Phase 1 Interventional

Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

NCT03739931
View directory record Official record
Conditions
Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma
Interventions
mRNA-2752, Durvalumab
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
16
States / cities
San Francisco, California • Santa Monica, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 29, 2026, 5:43 PM EDT
Terminated No phase listed Observational

FNA Tumor Sampling for CD137 Modulation: A Pilot Study

NCT01114256
View directory record Official record
Conditions
Head and Neck Cancer, Breast Cancer, Head and Neck Cancers, Non-Hodgkin Lymphoma, Colorectal Adenocarcinoma
Interventions
FNA Biopsy
Procedure
Lead sponsor
Stanford University
Other
Eligibility
21 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2017 · Synced Oct 29, 2026, 5:43 PM EDT
Terminated Phase 2 Interventional

An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+

NCT01116245
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia
Interventions
ADXS11-001 (Lm-LLO-E7), Placebo Control
Biological · Drug
Lead sponsor
Advaxis, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
15
States / cities
Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2016 · Synced Oct 29, 2026, 5:43 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Sorafenib/Cetuximab in Head and Neck Cancer

NCT00815295
View directory record Official record
Conditions
Squamous Cell Cancer
Interventions
Sorafenib, Cetuximab
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 8, 2014 · Synced Oct 29, 2026, 5:43 PM EDT
Completed Phase 2 Interventional

Efficacy of Hyperbaric Oxygen Therapy in Laryngectomy Patients

NCT00026975
View directory record Official record
Conditions
Laryngeal Cancer
Interventions
Hyperbaric Oxygen
Procedure
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 18, 2006 · Synced Oct 29, 2026, 5:43 PM EDT
Completed No phase listed Observational

Sexually Transmitted Infections Among African American Women Who Have Sex With Women

NCT01043081
View directory record Official record
Conditions
Sexually Transmitted Infections, HIV Infections
Interventions
Not listed
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated May 11, 2016 · Synced Oct 29, 2026, 5:43 PM EDT
Terminated Not applicable Interventional Results available

Assessing the da Vinci® Robotic Surgical System for Surgery of the Upper Aerodigestive Tract

NCT00721539
View directory record Official record
Conditions
Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Head and Neck Cancers
Interventions
da Vinci Surgical Robot Platform, Transoral Robotic Surgery
Device · Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2016 · Synced Oct 29, 2026, 5:43 PM EDT
Completed Phase 2 Interventional

SGN-00101 Vaccine in Treating Human Papillomavirus in Patients Who Have Abnormal Cervical Cells

NCT00091130
View directory record Official record
Conditions
Atypical Squamous Cells of Undetermined Significance, Cervical Cancer, High-grade Squamous Intraepithelial Lesion, Low-grade Squamous Intraepithelial Lesion
Interventions
HspE7, placebo, laboratory biomarker analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 50 Years · Female only
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Oct 29, 2026, 5:43 PM EDT
Terminated Phase 1Phase 2 Interventional

Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer

NCT03786081
View directory record Official record
Conditions
Cervical Cancer
Interventions
Tisotumab Vedotin, Bevacizumab, Pembrolizumab, Carboplatin
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
25
States / cities
Phoenix, Arizona • Orange, California • Sylmar, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 29, 2026, 5:43 PM EDT
Active, not recruiting Phase 2 Interventional

Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies

NCT04925544
View directory record Official record
Conditions
Nasopharyngeal Cancer, Epstein-Barr Virus Related Carcinoma
Interventions
VK-2019
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 29, 2026, 5:43 PM EDT
Completed Phase 2Phase 3 Interventional

A Study of Amolimogene (ZYC101a) in Patients With High Grade Cervical Intraepithelial Lesions of the Uterine Cervix

NCT00264732
View directory record Official record
Conditions
Uterine Cervical Dysplasia
Interventions
Amolimogene, Placebo
Drug · Other
Lead sponsor
Eisai Inc.
Industry
Eligibility
13 Years to 25 Years · Female only
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
26
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Oct 29, 2026, 5:43 PM EDT
Recruiting Not applicable Interventional

Velopharyngeal Dysfunction in Head & Neck Cancer Patients, Pilot Study

NCT07264036
View directory record Official record
Conditions
Velopharyngeal Insufficiency, Head and Neck Cancer, Survivorship, Dysphagia, Speech Disorder
Interventions
Pharyngeal Wall Augmentation Injection
Procedure
Lead sponsor
Vanessa Torrecillas
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 29, 2026, 5:43 PM EDT
Recruiting Phase 1 Interventional

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

NCT06479811
View directory record Official record
Conditions
Sinonasal Neuroendocrine Carcinoma, Nasopharyngeal Carcinoma, Esthesioneuroblastoma, Olfactory Neuroblastoma, Somatostatin Receptor Positive, Small Cell Lung Cancers, Pheochromocytoma/Paragangliomas, Kidney Cancers, Head and Neck Tumors, Gastrointestinal Neuroendocrine Tumors
Interventions
[212Pb]VMT-alpha-NET, [203Pb]VMT-alpha-NET, 68Ga-DOTATATE
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 29, 2026, 5:43 PM EDT
Completed Not applicable Interventional Results available

Tissue and Hematopoietic/Mesenchymal Stem Cell for Humanized Xenograft Studies in Melanoma and Squamous Head and Neck Cancer

NCT02331134
View directory record Official record
Conditions
Malignant Melanoma, Head and Neck Cancer
Interventions
Filgrastim
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 29, 2026, 5:43 PM EDT
Withdrawn Not applicable Interventional

Plastic Stents Compared With Metal Stents in Treating Patients With Malignant Dysphagia Caused by Esophageal Cancer or Gastroesophageal Junction Cancer

NCT00372450
View directory record Official record
Conditions
Esophageal Cancer, Gastrointestinal Complications
Interventions
management of therapy complications, quality-of-life assessment
Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Oct 29, 2026, 5:43 PM EDT
Completed Phase 2 Interventional Results available

S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction

NCT00086996
View directory record Official record
Conditions
Esophageal Cancer
Interventions
fluorouracil, oxaliplatin, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
143
States / cities
Mobile, Alabama • Anchorage, Alaska • Bentonville, Arkansas + 92 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2013 · Synced Oct 29, 2026, 5:43 PM EDT
Terminated Phase 1 Interventional

Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1

NCT04795713
View directory record Official record
Conditions
Advanced Solid Tumor, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
Interventions
MT-6402
Drug
Lead sponsor
Molecular Templates, Inc.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
16
States / cities
Duarte, California • Los Angeles, California • Newnan, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Oct 29, 2026, 5:43 PM EDT